Loading company…
VitaDX develops an AI-based urine test for detecting bladder cancer.
Founded in 2015 and based in Rennes, France, VitaDX develops VisioCyt® Bladder, an in vitro diagnostic device that uses AI and image processing to detect bladder cancer from a urine sample. The product has CE IVDR certification and has been available for prescription since early 2023. In August 2025, the company raised EUR 1.5 million from Go Capital and Odyssee Venture to support its rollout in France and prepare for entry into the US.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in